Robert A. Lafyatis, MD
Adjunct Professor
Boston University School of Medicine
Dept of Medicine
Rheumatology

MD, University of Cincinnati




Dr. Lafyatis carries out patient oriented research into the cause and treatment of systemic sclerosis. This includes early phase clinical trials into new therapeutic agents in patients with systemic sclerosis. He has been investigating the mechanisms of actions and markers of response for novel therapeutics, such as the B cell depleting agent, rituximab and the immunosuppressant agent, mycophenlate. Additional studies are aimed at identifying biomarkers in systemic sclerosis using microarray gene expression analysis of skin and blood in scleroderma patients. Ongoing biomarker studies include investigation into molecular markers of pulmonary hypertension in systemic sclerosis. Dr. Lafyatis also carries out basic research into the cause of fibrosis and vasculopathy in systemic sclerosis using patient samples and murine disease models. His studies have provided key insights into one widely used model of systemic sclerosis, the tight skin mouse. His studies are currently focused on understanding how autoimmunity and the innate immune system lead to fibrosis and vascular damage. This has recently led to the discovery of increased interferon-regulated gene expression in white blood cells of patients with systemic sclerosis. Ongoing research is aimed at better understanding the cause of altered gene expression by monocytes and other cells in the innate immune system.

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy volunteers and Subjects with Systemic Lupus Erythematosus
04/09/2015 - 04/08/2020 (Co-PI)
PI: Christina Lam, MD
Biogen Idec


A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
12/01/2015 - 11/30/2019 (Co-PI)
PI: Robert W. Simms, MD
Corbus Pharmaceuticals Holdings, Inc.


Scleroderma Clinical Repository (SCaR)
10/01/2014 - 09/30/2019 (PI)
Regeneron Pharmaceuticals, Inc.


ASSET: A Phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis - a double-blind, placebo-controlled, randomized controlled trial [IMI101-344]
03/31/2015 - 06/30/2019 (Subcontract PI)
Regents of the University of Michigan Bristol-Myers Squibb


Randomized, double-blind, placebo-controlled trial of IL1-Trap, Rilonacept, in Systemic Sclerosis-A Phase I/II Biomarker Trial
12/01/2011 - 02/05/2019 (PI)
Regeneron Pharmaceuticals, Inc.


Scleroderma Workshop
02/01/2010 - 01/31/2018 (PI)
MedImmune, Inc.


Nox4 Inhibitor in Systemic Sclerosis
11/14/2014 - 11/13/2017 (PI)
Mistral Therapeutics, Inc.


NIAMS: CORT
09/01/2011 - 08/31/2017 (PI of Sub-Project / SP)
PI: Robert W. Simms, MD
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5P50AR060780-05

Rheumatic Diseases Research Core Centers
09/01/2011 - 08/31/2017 (PI of Sub-Project / SP)
PI: Robert W. Simms, MD
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5P30AR061271-05

A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis-A Phase I/II Biomarker and Safety Trial
04/02/2015 - 04/01/2017 (PI)
PRISM Pharma Co Ltd


Showing 10 of 42 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs
2019 Mapping Age-Related Changes in the Lung 1U01HL145550-01
2019 Open chromatin and transcriptional regulation of dermal myofibroblasts in SSc 1R61AR076819-01
2019 Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension 5R21AR069285-03
2019 International Workshop on Scleroderma Research 5R13AR053784-09
2019 Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis 5P50AR060780-08 80
2019 Administrative Core 5P50AR060780-08-6914 80
2019 Project 1: Systemic Sclerosis Skin Biomarkers & Therapeutics 5P50AR060780-08-6918 80
2018 Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension 5R21AR069285-02
2018 International Workshop on Scleroderma Research 5R13AR053784-08
2018 Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis 5P50AR060780-07 80
Showing 10 of 60 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Pachera E, Assassi S, Salazar GA, Stellato M, Renoux F, Wunderlin A, Blyszczuk P, Lafyatis R, Kurreeman F, de Vries-Bouwstra J, Messemaker T, Feghali-Bostwick CA, Rogler G, van Haaften WT, Dijkstra G, Oakley F, Calcagni M, Schniering J, Maurer B, Distler JH, Kania G, Frank-Bertoncelj M, Distler O. Long noncoding RNA H19X is a key mediator of TGF-ß-driven fibrosis. J Clin Invest. 2020 Sep 01; 130(9):4888-4905. PMID: 32603313
     
  2. Li X, Kim SE, Chen TY, Wang J, Yang X, Tabib T, Tan J, Guo B, Fung S, Zhao J, Sembrat J, Rojas M, Shiva S, Lafyatis R, St Croix C, Alder JK, Di YP, Kass DJ, Zhang Y. Toll interacting protein protects bronchial epithelial cells from bleomycin-induced apoptosis. FASEB J. 2020 Jun 28. PMID: 32596871
     
  3. Bueno M, Papazoglou A, Valenzi E, Rojas M, Lafyatis R, Mora AL. Mitochondria, Aging, and Cellular Senescence: Implications for Scleroderma. Curr Rheumatol Rep. 2020 Jun 19; 22(8):37. PMID: 32562128
     
  4. Maehara T, Kaneko N, Perugino CA, Mattoo H, Kers J, Allard-Chamard H, Mahajan VS, Liu H, Murphy SJ, Ghebremichael M, Fox D, Payne AS, Lafyatis R, Stone JH, Khanna D, Pillai S. Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest. 2020 May 01; 130(5):2451-2464. PMID: 31990684
     
  5. Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V, Furst DE, Gordon J, Mayes M, Simms R, Lafyatis R, Martyanov V, Wood T, Whitfield ML, Constantine S, Lee E, Dgetluck N, White B. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis Rheumatol. 2020 Apr 26.View Related Profiles. PMID: 32336038
     
  6. Saygin D, Tabib T, Bittar HET, Valenzi E, Sembrat J, Chan SY, Rojas M, Lafyatis R. Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension. Pulm Circ. 2020 Jan-Mar; 10(1). PMID: 32166015
     
  7. Lear TB, Lockwood KC, Larsen M, Tuncer F, Kennerdell JR, Morse C, Valenzi E, Tabib T, Jurczak MJ, Kass DJ, Evankovich JW, Finkel T, Lafyatis R, Liu Y, Chen BB. Kelch-like protein 42 is a profibrotic ubiquitin E3 ligase involved in systemic sclerosis. J Biol Chem. 2020 Mar 27; 295(13):4171-4180. PMID: 32071084
     
  8. Mallampalli RK, Li X, Jang JH, Kaminski T, Hoji A, Coon T, Chandra D, Welty S, Teng Y, Sembrat J, Rojas M, Zhao Y, Lafyatis R, Zou C, Sciurba F, Sundd P, Lan L, Nyunoya T. Cigarette smoke exposure enhances transforming acidic coiled-coil-containing protein 2 turnover and thereby promotes emphysema. JCI Insight. 2020 01 30; 5(2). PMID: 31996486
     
  9. Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, Oesterreich S, Chen W, Lafyatis R, Bruno TC, Ferris RL, Vignali DAA. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity. 2020 01 14; 52(1):183-199.e9. PMID: 31924475
     
  10. Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox DA, Furst DE. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol. 2020 01; 72(1):125-136.View Related Profiles. PMID: 31342624
     
Showing 10 of 191 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 191 publications over 31 distinct years, with a maximum of 17 publications in 2016

YearPublications
19881
19897
19908
19919
19921
19932
19944
19961
19971
19982
19992
20001
20024
20031
20043
20052
20067
20078
20084
20098
201014
20115
201210
201310
20149
20159
201617
20179
201810
201913
20209

Contact for Mentoring:

75 E. Newton St Evans Building
Boston MA 02118
Google Map


Lafyatis's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department